Visualization of Critical Limits and Critical Values Facilitates Interpretation

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2025 Mar 13

PMID 40075851

Authors

Ania Shah

Jenna Dohner

Kaifeng Cheng

Maria Garcia

Gerald J Kost

Affiliations

Soon will be listed here.

Abstract

This study aimed to analyze critical limit and critical value test lists from major US medical centers, identify changes in quantitative critical limit thresholds since 1990, document notification priorities for qualitative and new listings, and visualize information alongside clinical thresholds and pathophysiological trends. A systematic search was conducted, acquiring 50 lists of critical limits and critical values from university hospitals, Level 1 trauma centers, centers of excellence, and high-performing hospitals across the US. Lists were obtained through direct contact or web-accessible postings. Statistical analysis used the Kruskal-Wallis non-parametric test and Student's -test to determine significant differences between 1990 and 2024 critical limits. Statistically significant differences were identified in various clinical tests between 1990 and 2024, comprising glucose, calcium, magnesium, CO content, blood gas parameters, hematology, and coagulation tests. Ranges for critical limits narrowed for several tests, and new measurands were added. Cardiac biomarkers were infrequently listed. Point-of-care testing (POCT) listings were sparse and showed significant differences from main lab values in the high median critical limit for glucose Visualizing this information has potential benefits, including ease of interpretation, which can improve patient care, reduce inconsistencies, and enhance the efficiency and quality of healthcare delivery.

References

Pasquel F, Umpierrez G . Hyperosmolar hyperglycemic state: a historic review of the clinical presentation, diagnosis, and treatment. Diabetes Care. 2014; 37(11):3124-31. PMC: 4207202. DOI: 10.2337/dc14-0984. View

Kost G . The significance of ionized calcium in cardiac and critical care. Availability and critical limits at US medical centers and children's hospitals. Arch Pathol Lab Med. 1993; 117(9):890-6. View

Blumberg N, Heal J, Phillips G . Platelet transfusions: trigger, dose, benefits, and risks. F1000 Med Rep. 2010; 2:5. PMC: 2874899. DOI: 10.3410/M2-5. View

Ahluwalia S, Damberg C, Silverman M, Motala A, Shekelle P . What Defines a High-Performing Health Care Delivery System: A Systematic Review. Jt Comm J Qual Patient Saf. 2017; 43(9):450-459. PMC: 8493928. DOI: 10.1016/j.jcjq.2017.03.010. View

Elrod J, Fortenberry Jr J . Centers of excellence in healthcare institutions: what they are and how to assemble them. BMC Health Serv Res. 2017; 17(Suppl 1):425. PMC: 5516836. DOI: 10.1186/s12913-017-2340-y. View

Bleeker J, Hogan W . Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies. Thrombosis. 2011; 2011:536062. PMC: 3200282. DOI: 10.1155/2011/536062. View

Sahadeo P, Dym A, Berry L, Bahar P, Singla A, Cheta M . The Best of Both Worlds: Eliminating Creatine Kinase-Muscle/Brain (CK-MB) Testing in the Emergency Department Leads to Lower Costs Without Missed Clinical Diagnoses. Cureus. 2021; 13(5):e15150. PMC: 8214836. DOI: 10.7759/cureus.15150. View

Torres P, Helmstetter J, Kaye A, Kaye A . Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner J. 2015; 15(1):58-69. PMC: 4365849. View

Kost G . Critical limits for urgent clinician notification at US medical centers. JAMA. 1990; 263(5):704-7. View

10.

Kost G . Critical limits for emergency clinician notification at United States children's hospitals. Pediatrics. 1991; 88(3):597-603. View

11.

Iurlo A, Cattaneo D, Bucelli C, Baldini L . New Perspectives on Polycythemia Vera: From Diagnosis to Therapy. Int J Mol Sci. 2020; 21(16). PMC: 7461104. DOI: 10.3390/ijms21165805. View

12.

Hanna D, Griswold P, Leape L, Bates D . Communicating critical test results: safe practice recommendations. Jt Comm J Qual Patient Saf. 2005; 31(2):68-80. DOI: 10.1016/s1553-7250(05)31011-7. View

13.

Roussos C, Koutsoukou A . Respiratory failure. Eur Respir J Suppl. 2003; 47:3s-14s. DOI: 10.1183/09031936.03.00038503. View

14.

Hachey B, Kontos M, Newby L, Christenson R, Peacock W, Brewer K . Trends in Use of Biomarker Protocols for the Evaluation of Possible Myocardial Infarction. J Am Heart Assoc. 2017; 6(9). PMC: 5634258. DOI: 10.1161/JAHA.117.005852. View

15.

Barbui T, Thiele J, Gisslinger H, Kvasnicka H, Vannucchi A, Guglielmelli P . The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018; 8(2):15. PMC: 5807384. DOI: 10.1038/s41408-018-0054-y. View

16.

Karin A, Kulasingam V, Chartier L, Ejumudo A, Wolff T, Brinc D . Recurring Critical Results and Their Impact on the Volume of Critical Calls at a Tertiary Care Center. J Appl Lab Med. 2021; 6(4):962-968. DOI: 10.1093/jalm/jfab001. View

17.

Kost G . Using critical limits to improve patient outcome. MLO Med Lab Obs. 1993; 25(3):22-7. View

18.

Florkowski C, Don-Wauchope A, Gimenez N, Rodriguez-Capote K, Wils J, Zemlin A . Point-of-care testing (POCT) and evidence-based laboratory medicine (EBLM) - does it leverage any advantage in clinical decision making?. Crit Rev Clin Lab Sci. 2017; 54(7-8):471-494. DOI: 10.1080/10408363.2017.1399336. View

19.

Schifman R, Howanitz P, Souers R . Point-of-Care Glucose Critical Values: A Q-Probes Study Involving 50 Health Care Facilities and 2349 Critical Results. Arch Pathol Lab Med. 2016; 140(2):119-24. DOI: 10.5858/arpa.2015-0058-CP. View

20.

Wang X, Zhang F, Zhang C, Zheng L, Yang J . The Biomarkers for Acute Myocardial Infarction and Heart Failure. Biomed Res Int. 2020; 2020:2018035. PMC: 6988690. DOI: 10.1155/2020/2018035. View